title: Cisplatin toxicity reduced in human cultured renal tubular cells by oxygen pretreatment.
abstract: Cisplatin is an effective and widely used chemotherapy agent and its side effects, particularly nephrotoxicity, limit its usage and related platinum-based drugs. Cisplatin nephrotoxicity is mainly due to extremely increase in reactive oxygen species (ROS) generation leading to kidney tubular cell death. Preconditioning with oxidative stress has been demonstrated to stimulate the cellular adaptation to subsequent severe oxidative stress. Short term oxygen pre-exposure as a mild oxidative stress may enhance some endogenous defense mechanisms, so its effect on Cisplatin induced cell death was investigated in present research. We studied the effects of hyperoxic environment pre-exposure on Cisplatin toxicity in an in-vitro model of cultured human embryonic tubular epithelial cells (AD293). Viability of AD293 cells, as evaluated by MTT-assay, was affected by Cisplatin in a time (1-4 h) dependent model. Biochemical markers of cell apoptosis were evaluated using immunoblotting. Pretreatment with nearly pure oxygen (≥90%) for 2 h significantly reduced the level of cell damage. Activated caspase 3 and Bax/Bcl-2 ratio were significantly increased in Cisplatin-treated cells. Oxygen pretreatment inhibited caspase 3 activation and decreased Bax/Bcl-2 ratio. Oxygen pre-treatment itself not showed any cytotoxicity in exposure times up to 3 h. Our data indicate that hyperoxic preconditioning reduces Cisplatin toxicity in cultured human tubular epithelial cells. The exact mechanism of protection is unclear, though enhancement of some endogenous defense mechanisms and subsequently scavenging of free oxygen radicals may play an important role.
authors.affiliation: Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences , Khorramabad , Iran .
authors.forename: Ayat
authors.initials: A
authors.lastname: Kaeidi
authors.forename: Bahram
authors.initials: B
authors.lastname: Rasoulian
authors.forename: Zahra
authors.initials: Z
authors.lastname: Hajializadeh
authors.forename: Soheila
authors.initials: S
authors.lastname: Pourkhodadad
authors.forename: Maryam
authors.initials: M
authors.lastname: Rezaei
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D015153:Blotting, Western; D053148:Caspase 3 / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival; D002945:Cisplatin / Q000633:toxicity*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000201:enzymology / Q000517:prevention & control*; D010100:Oxygen / Q000627:therapeutic use*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D051028:bcl-2-Associated X Protein; D053148:Caspase 3; D002945:Cisplatin; D010100:Oxygen